DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney disease and acute ischemic stroke. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC." Source
No articles found.
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
We are a pharmaceutical company currently in the preclinical stage, dedicated to d...
We are a pharmaceutical company currently in th...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...
Celgene Corporation, headquartered in Summit, N...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
Proteon Therapeutics is working to deliver a new future for patients and families ...
Proteon Therapeutics is working to deliver a ne...
Join the National Investor Network and get the latest information with your interests in mind.